However, independent studies have shown that compared to CBL wild-type AML cells, CBL mutant AML cells are more sensitive to quizartinib (a FLT3 inhibitor) than ruxolitinib (a JAK2 inhibitor) (Lv et al., 2017). Here, FLT3 is linked to acute myeloid leukemia.